索拉非尼治疗晚期肾透明细胞癌的临床观察

王美(金监); 王雅琦; 涂建仁; 邱志敏; 邓觐云

doi:10.3969/j.issn.1672-2353.2011.11.037

索拉非尼治疗晚期肾透明细胞癌的临床观察

江西省肿瘤医院,江西,南昌,330029

详细信息

中图分类号: R737.11
计量
- 文章访问数: 239
- HTML全文浏览量: 27
- PDF下载量: 6
出版历程
- 发布日期: 2011-09-29

The clinical observation of Sorafenib in the treatment of metastatic renal clear cell carcinoma

摘要

摘要: 目的观察索拉非尼治疗晚期肾癌的疗效和安全性.方法 22例晚期转移性肾透明细胞癌患者给予单药口服索拉非尼治疗9～23个月,每8周评定疗效,并登记、处理不良反应.结果部分缓解(PR)1例、疾病稳定(SD)15例、疾病进展(PD)4例、死亡2例,无完全缓解(CR)病例.主要不良反应有手足综合征、胃肠道反应及血压升高等.结论索拉非尼能够稳定病情,延长晚期RCC患者无进展生存时间,且毒副反应轻,耐受性好.
- 索拉非尼 /
- 肾细胞癌 /
- 靶向治疗

HTML全文

参考文献(11)

DeVita V T Jr, Hellman S, Rosenberg S A. Cancer Principles and Practice of Oncology [M]. Philadelphia, Pa:Lippincott W illiams&W ilkins, 2005.1140.

Geertsen P F, Gore M E, Negrier S, et a1. Safety and efficacy of subcutaneous and continuous intravenous infusion rlL-2 in patients with metastatic renal cell carcinoma [J]. British Journal of Cancer, 2004(6):1156.doi: 10.1038/sj.bjc.6601709.

Flanigan R C, Mickisch G, Sylvester R, et a1. Cytoreductive nephrectomy in patients with metastatic renal cancer.A combined analysis [J]. The Journal of Urology, 2004(3):1071.doi: 10.1097/01.ju.0000110610.61545.ae.

刘欣, 姚宝庚, 朱剑南. 肾癌术后应用生物治疗的疗效观察 [J]. 实用临床医药杂志, 2009, (21):106.doi: 10.3969/j.issn.1672-2353.2009.21.050.

Wilhelm S M, Carter C, Tang L. BAY 43-9006 exhibits broad spectrum and antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [J]. Cancer Research, 2004, (19):7099.doi: 10.1158/0008-5472.CAN-04-1443.

彭大为, 黄仕思. 索拉非尼治疗前后原发性肝癌患者外周血T淋巴细胞和NK细胞的变化及临床意义 [J]. 广东医学, 2010(6):783.doi: 10.3969/j.issn.1001-9448.2010.06.051.

Ratain M J, Eisen T, Stadler W M. PhaseⅡplacebo-controlled randomized discontinuatoin trial of Sorafenib in patients with advanced renal cell carcinoma [J]. Journal of Clinical Oncology, 2006, (16):2505.doi: 10.1200/JCO.2005.03.6723.

Escudier B, Eisen T, Bukowski R M. Sorafenib in advanced clear-cell carcinoma [J]. the New England Journal of Medicine, 2007(2):125.doi: 10.1056/NEJMoa060655.

周爱萍, 孙燕. 多靶点抗肿瘤新药索拉非尼的研究进展 [J]. 癌症进展, 2006(6):529.doi: 10.3969/j.issn.1672-1535.2006.06.012.

张海梁, 叶定伟, 姚旭东. 索拉非尼治疗转移性肾细胞癌20例初步结果 [J]. 中国癌症杂志, 2008(2):135.doi: 10.3969/j.issn.1007-3639.2008.02.012.

Strumberg D, Awada A, Hirte H. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumors:Is rash associated with treatment outcome [J]. European Journal of Cancer, 2006(4):548.doi: 10.1016/j.ejca.2005.11.014.

施引文献

资源附件(0)

计量

文章访问数: 239
HTML全文浏览量: 27
PDF下载量: 6
被引次数: 0

索拉非尼治疗晚期肾透明细胞癌的临床观察

计量

出版历程

The clinical observation of Sorafenib in the treatment of metastatic renal clear cell carcinoma

计量

出版历程

目录